高内涵筛检市场 - 全球产业规模、份额、趋势、机会及预测（按产品、应用、最终用户、地区和竞争格局划分），2021-2031年

全球高内涵筛检市场预计将从 2025 年的 12.8 亿美元成长到 2031 年的 20.2 亿美元，复合年增长率达到 7.89%。

高内涵筛检(HCS) 将自动化显微镜技术与先进的影像分析结合，能够量化细胞模型中的表型变异，从而同时评估众多生物学参数。这种分析能力对于在药物研发早期阶段发现有前景的候选药物并确定其毒性特征至关重要。该市场的成长主要源于降低药物研发高失败率的需求以及对更具预测性和生理相关性的检测方法的需求。产业对创新的大量投资也支撑了这一成长势头；例如，欧洲製药工业协会联合会 (EFPIA) 报告称，欧洲製药业将在 2024 年投入 550 亿欧元用于研发。

儘管成长要素强劲，但市场仍面临与数据管理和分析复杂性相关的重大障碍。由于每台筛检都会产生Terabyte的高解析度影像数据，处理和储存这些资讯所需的基础设施和专业的生物资讯技术构成了一个资源密集的瓶颈。这种技术难题推高了整体拥有成本，并有可能阻碍小规模实验室和研究机构采用高内涵成像技术。

市场驱动因素

製药和生技领域研发投入的不断成长是全球高内涵筛检市场的主要驱动力。面对专利到期，各公司正将资金集中投入早期药物发现基础设施建设，以补充其研发管线，并投资收购对高通量检测至关重要的自动化显微镜平台。诺华公司2025年4月发布的新闻稿《诺华将扩大在美国的研发和生产规模》就鲜明地反映了这一趋势。新闻稿宣布了一项为期五年、总额达230亿美元的战略投资，旨在加强研发能力，凸显了该行业对先进筛检技术在高效识别候选治疗药物方面的依赖。

人工智慧 (AI) 和机器学习的融合进一步加速了这些技术的应用，解决了影像资料分析中的关键瓶颈。现代筛检系统产生大量资料集，传统方法难以大规模处理。因此，人工智慧演算法对于快速表型分析至关重要。这种技术融合正在吸引大量资金用于药物发现的数位化。例如，在2025年3月题为「Isomorphic Labs宣布获得6亿美元资金筹措」的新闻稿中，Isomorphic Labs宣布已获得6亿美元融资，用于扩展其用于新型治疗药物设计的AI引擎。这些工具的影响在监管效率的提高上显而易见；2025年，美国食品药物管理局(FDA) 药物评价与研究中心报告称，上年度已核准50种新药上市，这表明筛检的化合物已成功实用化。

市场挑战

全球高内涵筛检市场在资料管理和分析复杂性方面面临许多挑战。由于筛检平台会产生Terabyte的高解析度影像，庞大的资讯量造成了营运瓶颈，需要大规模的储存基础设备和专业的生物资讯技术。这显着增加了整体拥有成本，使得这项技术对于资金有限的小规模实验室和研究机构而言难以负担。因此，处理这些资料集所需的高资源消耗阻碍了高内涵技术的广泛应用，直接限制了其在成本敏感领域的市场扩张。

处理复杂生物数据方面普遍存在的行业难题进一步加剧了这种技术壁垒。根据皮斯托亚联盟（Pistoia Alliance）的数据显示，52%的生命科学专业人士认为「低品质且管理不善的数据集」是2024年采用先进分析技术的主要障碍。这项数据凸显了数据挑战的严峻性，因为各机构都在努力维护有效筛检所需的数位化环境。如果潜在用户无法克服这些数据处理障碍，他们将被迫放弃采用高内涵分析方法，从而减缓市场的整体成长速度。

市场趋势

微流体晶片器官筛检技术的兴起标誌着检测方法向生理相关性检测的关键转变，这种检测方法比传统的二维培养方法更能有效地模拟人体组织结构。这一趋势的根本驱动力在于业界迫切需要以人为中心的系统取代动物模型，以便在药物研发早期阶段准确预测药物的毒性和疗效。监管机构认识到微生理系统在安全性评估方面具有更优的预测效度，因此正在积极推动这一转变。根据美国食品药物管理局（FDA）于2025年4月发布的题为「FDA宣布计划逐步取消单株抗体和其他药物的动物试验要求」的新闻稿，该机构已正式推出蓝图，以与人体相关的方法取代动物试验，尤其强调推广使用晶片器官系统来提高药物安全性并降低研发成本。

同时，CRISPR-Cas9基因编辑技术与高内涵检测的结合，透过实现对基因功能的无偏差、大规模分析，正在革新功能基因体学。将精准的基因操作与表型成像相结合，使研究人员能够将特定的基因突变与细胞表型直接关联起来，从而促进目标的可靠识别和检验。这种方法超越了简单的化合物筛检，以前所未有的规模提供了对疾病路径机制的深入理解。正如2025年7月麻省理工学院新闻报导《科学家应用光学混合CRISPR筛检鑑定新型伊波拉候选药物》报导的那样，研究人员利用高内涵成像技术筛检了约4000万个经CRISPR基因编辑破坏的人类细胞，并成功鑑定了数百种能够改变病毒感染水平的宿主蛋白。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球高内涵筛检市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（设备、耗材、软体、服务）
  • 依应用领域（筛检、复筛检、标靶辨识与检验、毒性测试、化合物分析等）
  • 依最终用户（製药/生技公司、学术/政府机构、合约研究组织）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美高内涵筛检市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲高内涵筛检市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区高内涵筛检市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东与非洲高内涵筛检市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲高内涵筛检市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球高内涵筛检市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Danaher Corporation
• Perkinelmer Inc.
• Thermo Fisher Scientific Inc.
• Becton, Dickinson and Company
• Agilent Technologies, Inc.
• Bio-Rad Laboratories Inc.
• Yokogawa Electric Corporation
• Merck KGaA
• Tecan Group Ltd.
• BioTek Instruments, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global High Content Screening Market is projected to expand from USD 1.28 Billion in 2025 to USD 2.02 Billion by 2031, achieving a CAGR of 7.89%. High Content Screening (HCS) combines automated microscopy with sophisticated image analysis to quantify phenotypic variations in cellular models, facilitating the simultaneous assessment of numerous biological parameters. This analytical capacity is crucial for detecting viable drug candidates and defining toxicity profiles during the early stages of development. The market is primarily propelled by the necessity to lower high attrition rates in drug discovery and the demand for assays that are more predictive and physiologically relevant. This momentum is underpinned by significant industry spending on innovation; for instance, the European Federation of Pharmaceutical Industries and Associations reported that the pharmaceutical sector invested €55 billion in research and development across Europe in 2024.

Despite these powerful growth drivers, the market encounters a major obstacle related to the complexity of data management and analysis. The production of terabytes of high-resolution image data during each screen creates a bottleneck, as the infrastructure and specialized bioinformatics expertise needed to process and store this information are resource-heavy. This technical difficulty raises the total cost of ownership and threatens to hinder the adoption of high content technologies within smaller laboratories and research institutions.

Market Driver

Increasing investments in pharmaceutical and biotechnology R&D act as the primary catalyst for the Global High Content Screening Market. Faced with patent expirations, companies are directing capital toward early-stage discovery infrastructure to replenish their pipelines, funding the acquisition of automated microscopy platforms essential for high-throughput assays. This trend is highlighted by Novartis's April 2025 press release, 'Novartis to Expand US-Based R&D and Manufacturing,' which announced a strategic commitment of $23 billion over five years to enhance research capabilities, underscoring the sector's reliance on advanced screening for the efficient identification of therapeutic candidates.

The adoption of these technologies is further accelerated by the integration of artificial intelligence and machine learning, which address critical bottlenecks in image data analysis. Modern screening systems produce massive datasets that traditional methods cannot process at scale; consequently, AI algorithms have become indispensable for rapid phenotypic profiling. This technological convergence is attracting significant capital aimed at digitizing drug discovery. For example, Isomorphic Labs announced in a March 2025 press release, 'Isomorphic Labs announces $600 million funding,' that it had secured $600 million to expand its AI engine for designing novel therapeutics. The impact of these tools is evident in regulatory productivity; the U.S. Food and Drug Administration's Center for Drug Evaluation and Research reported in 2025 that 50 novel drugs were approved in the preceding year, demonstrating the successful translation of screened compounds.

Market Challenge

The Global High Content Screening Market confronts a significant hurdle regarding the complexity of data management and analysis. Since screening platforms generate terabytes of high-resolution imagery, the immense volume of information creates an operational bottleneck that necessitates extensive storage infrastructure and specialized bioinformatics expertise. This requirement drastically inflates the total cost of ownership, rendering the technology financially impractical for smaller laboratories and research institutions with limited capital. Consequently, the high resource intensity needed to process these datasets restricts the broader adoption of high-content technologies, directly limiting market expansion in cost-sensitive sectors.

This technical barrier is emphasized by widespread industry difficulties in handling complex biological data. According to the Pistoia Alliance, in 2024, 52% of life science professionals identified low-quality and poorly curated datasets as the main obstacle to implementing advanced analytical technologies. This statistic illustrates the magnitude of the data challenge, as organizations struggle to maintain the digital environment necessary for effective screening. When potential users cannot overcome these data processing obstacles, they are forced to forego high-content methods, thereby slowing the overall growth trajectory of the market.

Market Trends

The rise of microfluidic organ-on-chip screening technologies marks a pivotal shift toward physiologically relevant assays that mimic human tissue architecture more effectively than traditional 2D cultures. This trend is fundamentally driven by the industry's urgent need to replace animal models with human-centric systems that can accurately predict drug toxicity and efficacy earlier in the pipeline. Regulatory bodies are actively catalyzing this transition, acknowledging that microphysiological systems offer superior predictive validity for safety assessments. According to the U.S. Food and Drug Administration's April 2025 press release, 'FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs,' the agency formally introduced a roadmap to replace animal testing with human-relevant methods, specifically promoting the use of organ-on-a-chip systems to improve drug safety and reduce R&D costs.

Simultaneously, the incorporation of CRISPR-Cas9 gene editing into high content assays is revolutionizing functional genomics by enabling the unbiased, large-scale interrogation of gene function. By combining precise genetic perturbations with phenotypic imaging, researchers can now directly link specific genetic alterations to cellular phenotypes, facilitating robust target identification and validation. This approach moves beyond simple compound screening to provide a deep mechanistic understanding of disease pathways at a scale previously unattainable. As noted by MIT News in July 2025 in the article 'Scientists apply optical pooled CRISPR screening to identify potential new Ebola drug targets,' researchers successfully utilized high-content imaging to screen approximately 40 million CRISPR-perturbed human cells, identifying hundreds of host proteins that alter viral infection levels.

Key Market Players

• Danaher Corporation
• Perkinelmer Inc.
• Thermo Fisher Scientific Inc.
• Becton, Dickinson and Company
• Agilent Technologies, Inc.
• Bio-Rad Laboratories Inc.
• Yokogawa Electric Corporation
• Merck KGaA
• Tecan Group Ltd.
• BioTek Instruments, Inc.

Report Scope

In this report, the Global High Content Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

High Content Screening Market, By Product

• Instruments
• Consumables
• Software
• Services

High Content Screening Market, By Application

• Primary and Secondary Screening
• Target Identification & Validation
• Toxicity Studies
• Compound Profiling
• Others

High Content Screening Market, By End User

• Pharmaceutical and Biotechnology Companies
• Academic and Government Institutions
• Contract Research Organization

High Content Screening Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global High Content Screening Market.

Available Customizations:

Global High Content Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global High Content Screening Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Consumables, Software, Services)
  • 5.2.2. By Application (Primary and Secondary Screening, Target Identification & Validation, Toxicity Studies, Compound Profiling, Others)
  • 5.2.3. By End User (Pharmaceutical and Biotechnology Companies, Academic and Government Institutions, Contract Research Organization)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America High Content Screening Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States High Content Screening Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada High Content Screening Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico High Content Screening Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe High Content Screening Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany High Content Screening Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France High Content Screening Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom High Content Screening Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy High Content Screening Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain High Content Screening Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific High Content Screening Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China High Content Screening Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India High Content Screening Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan High Content Screening Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea High Content Screening Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia High Content Screening Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa High Content Screening Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia High Content Screening Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE High Content Screening Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa High Content Screening Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America High Content Screening Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil High Content Screening Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia High Content Screening Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina High Content Screening Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global High Content Screening Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Danaher Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Perkinelmer Inc.
• 15.3. Thermo Fisher Scientific Inc.
• 15.4. Becton, Dickinson and Company
• 15.5. Agilent Technologies, Inc.
• 15.6. Bio-Rad Laboratories Inc.
• 15.7. Yokogawa Electric Corporation
• 15.8. Merck KGaA
• 15.9. Tecan Group Ltd.
• 15.10. BioTek Instruments, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer